Trump admin mulls 'severe restrictions' on US pharmas licensing Chinese meds: NYT

The Trump administration is reportedly considering a draft executive order to impose "severe restrictions" on investigational drugs from China, aiming to increase national security scrutiny on U.S. pharma licensing deals with Chinese biotechs, mandate more rigorous FDA review of China-sourced clinical data, and boost domestic drug production. This potential policy shift, backed by U.S. biotech investors concerned by China's growing innovation influence and associated IP/regulatory risks, could significantly impact the U.S.-China biopharma landscape, despite the White House denying active consideration of the order.

Analysis

A draft executive order, reportedly under consideration by the Trump administration, signals significant potential disruption for the U.S. biopharma sector by proposing "severe restrictions" on investigational drugs from China. The proposed measures, including national security reviews for licensing deals, heightened FDA scrutiny of Chinese clinical data, and preferential government purchasing for U.S.-made medicines, directly target a rapidly growing source of innovation for U.S. firms. The importance of this channel is underscored by Jefferies data showing China's share of out-licensing deal value rose to 32% in Q1 2025 from 21% in 2023-2024, with major recent deals like Pfizer's $1.25 billion agreement with 3SBio and AstraZeneca's $110 million collaboration with CSPC exemplifying the trend. While the White House has denied "actively considering" the order, its existence reflects underlying concerns from U.S. investors and previous administration policy regarding intellectual property security and strategic competition in the biotech space, creating a climate of regulatory uncertainty for companies leveraging Chinese assets to bolster their pipelines.

Key Decisions for Investors

• Investors should immediately review the exposure of pharmaceutical and biotech holdings to Chinese in-licensing deals and clinical trials, as the proposed policies could introduce significant delays, increased costs, and potential deal cancellations.
• Monitor U.S. political developments and policy statements closely, as the backing from influential investors and alignment with previous 'America First' rhetoric suggests this theme could resurface, creating headline risk for companies with significant China partnerships.
• Consider potential beneficiaries of a protectionist shift, such as U.S.-based contract development and manufacturing organizations (CDMOs) or companies focused on domestic production of essential medicines like antibiotics, which could gain from proposed government purchasing preferences.